Now, this licensing deal is really quite massive for Novavax, Inc. ( NVAX ), strategically speaking. For me, it validates the commercial/scientific value of their Matrix-M adjuvant beyond just Novavax’s own vaccine portfolio. There'sI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an ...